Pipeline & Products:

Sorbent’s robust CLP Platform offers an array of non-absorbed polymers that are chemically and bio-designed to selectively contribute or sequester targeted ions and fluid to deliver the prescribed therapeutic action in the gastro intestinal tract.

End Stage Renal Disease (ESRD)
CLP 1001 - ESRD**
(Removes Sodium, Potassium & Fluid)

Congestive Heart Failure (CHF)
CLP 1002 - CHF**
(Removes Sodium & fluid)

Chronic Kidney Disease (CKD)
CLP 1002 - CKD
(Removes Sodium & alters Potassium)

Essential Hypertension (HT)
CLP 1004 - HT
(Removes Sodium, Fluid & Supplement Potassium)

CLP - X
(other electrolyte/fluid imbalances)

** In May 2008, the FDA has designated the Investigation of Cross-Linked Polyelectrolyte (CLP) for patients undergoing Hemodialysis or in Congestive Heart Failure to Fast Track

Sorbent Therapeutics, Inc.
750 Bunker Court
Suite 900
Vernon Hills, IL 60061
Phone: 847-996-1500